|
Inflammatory Disease Therapeutics:
Pipelines and Competitive Dynamics comprehensively evaluates R&D efforts for six high-profile
immune/inflammatory disorders:
•
Rheumatoid Arthritis
•
Inflammatory Bowel Disease
•
Psoriasis
•
Lupus
•
Multiple Sclerosis
•
Asthma
The complexity of the immune system provides both opportunity
and challenge for those in the pharmaceutical industry trying
to manipulate it. There is a seemingly endless list of cytokines,
receptors, and enzymes that can be disrupted in patients with
autoimmune and inflammatory diseases, and the sheer number of
options leaves plenty of chances for large established players
and specialized newcomers alike to carve out niches for themselves.
However, the transition from brainstorm to marketed drug is
fraught with pitfalls. Targeting a single receptor or protein
often means being foiled by the immune system’s redundancy,
while cutting too wide a swath through the system can result
in unexpected side effects. Despite Herculean efforts to develop
newer and better agents for treating these conditions, frustratingly
few novel drugs have passed muster in clinical trials and reached
the market in the last decade. The market continues to eagerly
await safe and effective alternatives to existing therapies.
Inflammatory Disease Therapeutics examines the mechanisms of
immune/inflammatory disease, reviews the existing drug therapies
for each of the six diseases covered, and surveys some of drug
development attempts that have failed in the last several years.
The report then analyzes the range of new pharmacologic approaches
being explored for treating inflammatory disorders, focusing
on 14 pharma/biotech company pipelines for each of the six diseases
individually. New therapies to treat inflammatory diseases are
evaluated using SWOT analysis to compare emerging compounds with
standard therapies. These include an analysis of Bristol-Myers
Squibb’s abatacept, the next novel rheumatoid arthritis
treatment likely to be approved; a comparison of adhesion molecule
blockers with standard inflammatory bowel disease therapy; and
an evaluation of MBP peptide vaccines for multiple sclerosis
therapy, an approach that could arrest the disease process rather
than merely treating symptoms.
About the Author
Mark C. Via, an editor at CTB International Publishing, has
ten years’ experience writing and editing for pharmaceutical
trade publications. Mr. Via holds a B.A. degree in history from
Williams College.
| 
